Viridian Therapeutics Inc Stock Price, News & Analysis

Viridian Therapeutics, Inc. (NASDAQ: VRDN) announced an underwritten public offering of $175 million in common stock and series B preferred stock, with an additional $26.25 million option for underwriters. The funding aims to support clinical development programs and cover general corporate expenses. The series B preferred stock is convertible into common stock. Jefferies, SVB Securities, and Evercore ISI are managing the offering. The registration statement for this offering is effective, and the company emphasizes that the press release does not constitute an offer to sell securities.

Viridian Therapeutics (NASDAQ: VRDN) announced positive initial data from its ongoing Phase 1/2 trial of VRDN-001 for Thyroid Eye Disease (TED) and promising results from VRDN-002, which has an extended half-life. As of June 30, 2022, the company reported $161 million in cash and equivalents plus a $75 million credit facility, ensuring operational funding into 2024. R&D expenses rose to $21.7 million, contributing to a net loss of $29.5 million in Q2 2022. Future plans include advancing VRDN-001 to Phase 3 and initiating new trials with VRDN-002 and VRDN-003.

Viridian Therapeutics announced positive initial clinical data from the VRDN-001 Phase 1/2 trial for thyroid eye disease (TED). Results showed an 83% response rate in proptosis with a mean reduction of 2.4mm, and 75% of patients experienced complete resolution of diplopia. Notably, there were no serious adverse events reported, indicating a favorable safety profile. Additionally, enrollment for the 20mg/kg cohort is nearly complete, with data expected in Q4 2022. The company also provided insights into the extended half-life of another candidate, VRDN-002, highlighting its potential as a subcutaneous treatment.

Viridian Therapeutics, Inc. (Nasdaq: VRDN) announced on August 5, 2022, that its Compensation Committee approved the grant of stock options for 53,000 shares to two new employees as an inducement for joining the company. This grant, made outside the 2016 Equity Incentive Plan, aligns with Nasdaq Listing Rule 5635(c)(4). The exercise price matches the closing stock price on the grant date, with vesting over four years, starting with 25% after the first year and monthly thereafter. Viridian focuses on developing innovative treatments for serious diseases, notably its advanced program targeting thyroid eye disease.

Viridian Therapeutics, Inc. (Nasdaq: VRDN) announced a stock option grant to an employee for 14,000 shares as an inducement for employment. The grant, approved by the Compensation Committee, is outside the company's existing equity incentive plan but adheres to its terms. The exercise price matches the closing stock price on the grant date, July 1, 2022. The options will vest over four years, with 25% vesting after one year and the remainder in monthly installments, contingent on continued employment. Viridian focuses on developing treatments for serious diseases, including thyroid eye disease.

Viridian Therapeutics (NASDAQ: VRDN) appointed Carrie Melvin as Chief Operating Officer, a new role aimed at supporting the company's late-stage clinical development for its thyroid eye disease (TED) programs, VRDN-001 and VRDN-002. With over 20 years of experience in the biotech sector, Melvin's past roles include Senior Vice President of Clinical Development Operations at X4 Pharmaceuticals and Vice President at GSK, focusing on oncology. As part of her employment, she will receive an Inducement Grant of options to purchase 210,000 shares of common stock, vesting over four years.

Viridian Therapeutics (NASDAQ: VRDN) announced the approval of stock options for 266,000 shares to five new employees. These Inducement Grants, made on June 1, 2022, are designed to encourage new hires and are outside the 2016 Equity Incentive Plan. The exercise price matches the stock's closing price on the grant date and will vest over four years, starting with 25% after one year. Viridian focuses on developing treatments for serious conditions like thyroid eye disease, with its leading product candidate VRDN-001 targeting IGF-1R.

Viridian Therapeutics (NASDAQ: VRDN) announced that CEO Jonathan Violin, Ph.D., will participate in two fireside chats at upcoming conferences in New York. The first is at the Jefferies Healthcare Conference on June 8, 2022, at 11:30 am ET, followed by the JMP Securities Life Sciences Conference on June 15, 2022, at 3:30 pm ET. Investors can access live webcasts of both events via registration links. Viridian focuses on innovative therapies for serious diseases, with its lead program targeting thyroid eye disease.

Viridian Therapeutics (NASDAQ: VRDN) announced Phase 1/2 clinical trial updates for its lead product candidate, VRDN-001, targeting Thyroid Eye Disease (TED). Interim results show robust IGF-1 response with no significant adverse effects, suggesting the potential for lower dosing. The company ended Q1 2022 with $175 million in cash, expected to fund operations into 2024. R&D expenses increased to $17.7 million, contributing to a net loss of $25.7 million. The VRDN-002 trial is on track for top-line data in Q3 2022, aiming to enhance treatment convenience for TED patients.